Alkermes Unveils Long-Acting Injectable Proprietary Platform For Treatment Of Schizophrenia And Other CNS Disorders

{ Posted on Feb 07 2010 by admin }
Categories : Health News

Alkermes, Inc. (NASDAQ: ALKS) announced that it has developed a novel, proprietary LinkeRx™ technology platform to enable the creation of injectable extended-release versions of antipsychotics and other central nervous system (CNS) therapies. The company’s lead candidate that leverages this platform, designated as ALKS 9070, is a once-monthly, injectable, extended-release version of aripiprazole for the treatment of schizophrenia. Aripiprazole is commercially available under the name ABILIFY® for the treatment of a number of CNS disorders…


Related posts:

  1. Alkermes Unveils Long-Acting Injectable Proprietary Platform For Treatment Of Schizophrenia And Other CNS Disorders Alkermes, Inc. (NASDAQ: ALKS) announced that it has developed a...
  2. Alkermes Unveils Long-Acting Injectable Proprietary Platform For Treatment Of Schizophrenia And Other CNS Disorders Alkermes, Inc. (NASDAQ: ALKS) announced that it has developed a...
  3. Alkermes Unveils Long-Acting Injectable Proprietary Platform For Treatment Of Schizophrenia And Other CNS Disorders Alkermes, Inc. (NASDAQ: ALKS) announced that it has developed a...
  4. World’s Leading Experts In Schizophrenia To Meet At 26th Annual Pittsburgh Schizophrenia Conference Nov. 13 Internationally renowned experts in schizophrenia and other psychotic disorders, researchers...
  5. Scientists Demonstrate Link Between Genetic Defect And Brain Changes In Schizophrenia For decades, scientists have thought the faulty neural wiring that...
This entry was posted on Sunday, February 7th, 2010 at 1:00 am and is filed under Health News. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.

Post a Comment